Uncategorized
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts
Latest Ratings for VYGR Date Firm Action From To Nov 2021 Chardan Capital Maintains Neutral Oct 2021 Baird Upgrades Neutral Outperform Jun 2021 Compass Point Initiates Coverage On Buy View More Analyst Ratings for VYGR View the Latest Analyst Ratings read more
Dyne Therapeutics’ $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO Capital Markets initiates coverage on Dyne Therapeutics with an Outperform rating, an $84 target, and a projected $4.3 billion peak sales for DYNE-101. Latest Ratings for DYN Date Firm Action From To Oct 2020 JP Morgan Initiates Coverage On Overweight Oct 2020 Stifel Initiates Coverage On Buy Oct 2020 Jefferies Initiates Coverage On Buy…
Rubrik Next-Gen Data Backup And Recovery Platform Makes It A ‘Market Leader For Years,’ Analyst Upgrades Stock
RBRK stock upgraded by Rosenblatt analyst with PT of $77. Q4 expected to have 33% total revenue growth & 40% subscription revenue growth. RBRK stock up 6.41%. read more
What’s Going On With Micron Shares Wednesday?
Micron stock is trading higher on Wednesday amid a rebound in technology stocks following softer-than-expected CPI data for February. read more
Alphabet Shares Are Up Today: What’s Going On?
Alphabet Inc.’s Class C stock (NASDAQ: GOOG) is moving higher Wednesday as Google DeepMind unveils Gemini Robotics, a new AI-driven robotics platform powered by its Gemini 2.0 model. read more
